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Objectives
1) Overview the biology of SARS-CoV-2 vaccines
2) Safety and Efficacy of mRNA SARS-CoV-2 vaccines
3) Recommendations for SARS-CoV-2 vaccine
administration in specialized populations, including PLWH
4) Responding to FAQs
5) How to make strong recommendations

SARS-CoV-2

Overview of Vaccine Platforms in development
against COVID-19

mRNA Vaccines
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-43,448 participants
-82.9% White, 9.3% Black, 4.3% Asian
-28% Latinx
-151 sites
-6 countries (USA, Argentina, Brazil, South Africa, Germany,
Turkey)
-Randomized to receive either placebo or BNT162b2 mRNA
COVID vaccine in two intramuscular doses, 21 days apart
-Primary endpoints: efficacy of BNT162b2 against confirmed
Covid-19 with onset at least 7 days after the second dose,
efficacy in participants with and participants without evidence
of prior infection.
-Secondary endpoints: efficacy of BNT162b2 against severe
Covid-19.

“Appendix 8: Criteria for Allowing Inclusion of Participants With
Chronic Stable HIV, HCV, or HBV Infection”
-Potential participants with chronic stable HIV, HCV, or HBV
infection may be considered for inclusion if they fulfill the
following respective criteria:
• Confirmed stable HIV disease defined as
1) documented viral load <50 copies/mL
2) CD4 count >200 cells/mm3 within 6 months before
enrollment
3) and on stable antiretroviral therapy for at least 6 months.
-196 PLWH were recruited and included in the trial, but safety
results were analyzed separately and not included in published
manuscript

-30,420 participants
-79.2% White, 10.2% Black, 4.6% Asian
-20% Latinx
-Randomized to receive either placebo or mRNA-1273 COVID
vaccine in two intramuscular doses, 28 days apart
-Primary endpoints: efficacy of mRNA-1273 in preventing a first
occurrence of symptomatic COVID-19 with onset at least 14
days after the second injection
-Secondary endpoints: efficacy of mRNA-1273 against severe
Covid-19 (RR>30, HR>125, SpO2 <93%, P/F <300mmHg,
ARDS, SBP <90 mmHg/DBP <60 mmHg, or other clinically
significant renal, hepatic, or neurologic dysfunction)

“5.2.11 Immunosuppressive or immunodeficient state,
asplenia, recurrent severe infections”
-

-

HIV positive participants with CD4 count ≥350 cells/mm3
and an undetectable HIV viral load within the past year
Low level variations from 50-500 viral copies which do not
lead to changes in antiretroviral therapy [ART] are
permitted.
176 PLWH were recruited for the trial, 90 received vaccine,
86 received placebo. No COVID-19 cases were noted in
vaccine group after dose 2, one in placebo
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Underlying medical conditions that
increase a person’s risk of severe illness
from COVID-19

https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/evidence-table.html

Persons with underlying medical
conditions
-

-

Vaccine may be administered to persons with underlying
medical conditions who have no contraindications to
vaccination
- Immediate allergic reaction to COVID-19 vaccine or
ingredients
Phase 2/3 clinical trials demonstrate similar safety and
efficacy profiles in persons with underlying medical
conditions, including those that place them at increased risk
for severe COVID-19, compared to persons without
comorbidities
- Cancer, CKD, COPD, Down Syndrome, CHF,
Obesity, Pregnancy, T2DM

CDC Recommendations for People with
Immunodeficiency
“People with HIV and those with weakened immune systems
due to other illnesses or medication might be at increased risk
for severe COVID-19. They may receive a COVID-19 vaccine.
However, they should be aware of the limited safety data:
-Safety of mRNA COVID-19 vaccines for people who have
weakened immune systems in this group is not yet
available.
-People living with HIV were included in clinical trials,
though safety data specific to this group are not yet
available at this time.

CDC Recommendations for People with
Immunodeficiency
These individuals may still receive COVID-19 vaccine unless
otherwise contraindicated

Individuals should be counseled about:
– Unknown vaccine safety and efficacy profiles in
immunocompromised persons
– Potential for reduced immune responses
– Need to continue to follow all current guidance to protect
themselves against COVID-19

JCVI and BHIVA Recommendations for
People with Immunodeficiency
“Priority group 4: Clinically Extremely Vulnerable
-For people with HIV we advise that anybody with a CD4 count
less than 50 cells/mm3, or who has had an opportunistic illness
in the last 6 months, should be considered clinically extremely
vulnerable.
-All people, particularly those with a CD4 count in the range
50-200 cells/mm3, with additional risk factors should be
assessed on an individual basis and, if deemed extremely
clinically vulnerable, can be added to this category. Additional
risk factors to consider include:
- Detectable viral load
- Low nadir CD4 count
- Additional co-morbidities associated with moderate risk”
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FAQs:
Question: Can mRNA vaccines give someone COVID-19?
Answer: No. mRNA vaccines do not use the live virus
that causes COVID-19.

FAQs:
Question: Can mRNA vaccines interact with our DNA?
Answer: No.
1) mRNA never enters the nucleus of the cell, which is
where our DNA (genetic material) is kept.
2) The cell breaks down and gets rid of the mRNA
soon after it is finished using the instructions.

FAQs:
Question: Can we trust such a new vaccine technology?
Answer: Yes. While mRNA vaccines are a novel vaccine
platform, mRNA vaccines have been studied before for
flu, Zika, rabies, and cytomegalovirus (CMV). As soon
as the necessary information about the virus that causes
COVID-19 was available (January 2020), scientists
began designing the mRNA instructions for cells to build
the unique spike protein into an mRNA vaccine.

FAQs:
Question: Why do I need two shots?
Answer: Nearly all COVID-19 vaccines being studied in the
United States require two shots. The first shot starts
building protection, but everyone has to come back a few
weeks later for the second one to get the most protection
the vaccine can offer.

FAQs:
Question: I’ve already had COVID-19, should I still get the
vaccine?
Answer: Yes, its not recommended to administer vaccine
during acute infection, but can be given any time after
recovery. Natural immunity lasts ~90 days.

Unanswered Questions:
-

Long term immunity?
Long term side effects?
Persistent risk of transmission in vaccinated people?
Vaccine efficacy in patients with varying CD4 levels?
What percentage of the population needs to be vaccinated
to achieve herd immunity?
“When can I get a vaccine?”
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How to have effective COVID-19 vaccine
conversations
1) Start from a place of empathy or understanding
2) Assume patients will want to be vaccinated but may not
have all of their questions answered
3) Give your strong recommendation
a) “I strongly recommend you get a COVID-19 vaccine
once it is widely available…”
b) “…This shot is especially important for you because
of your [job/underlying health condition].”
c) “…I believe in this vaccine so strongly that I plan to
get it as soon as it is available.”
4) Listen to and respond to questions
5) Wrapping up the conversation
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